STOK

STOK is a late-stage clinical biotech, not an operating business you can value on its income statement. The eye-catching FY2025 revenue of $184M (+404.5%) is collaboration income from the Acadia and Biogen partnerships — lumpy, non-recurring milestone/upfront money, not product sales — so the 10.4x P/S and the near-breakeven -$6.88M net loss flatter the picture. The honest read is a company with zero approved products spending $138M a year on R&D, whose entire equity value rests on one asset: zorevunersen for Dravet syndrome, now in the global Phase 3 EMPEROR study with pivotal data not due until mid-2027 and a rolling NDA targeted for 1H2027. That is an unknowable binary you cannot underwrite from these numbers.

What the data does support is staying power into that readout. Balance sheet is clean — $352M equity against just $66M liabilities (0.19x leverage) and $306M of current assets (cash of $84.2M plus the rest in short-term investments) versus $57.9M current liabilities. The collaboration cash flow even turned operating cash flow positive ($45.6M), partly explaining why headline cash fell 34% as funds rotated into investments. So near-term funding risk is real but not acute; the company can likely reach the Phase 3 catalyst without an emergency raise, though the 10-K's explicit flag on 'our ability to procure sufficient funding,' the live $400M shelf/$150M ATM, and the 9.4% share-count growth all signal dilution ahead.